Infectious disease

Icon
ENTEROSGEL COLUMBIA LECTURE, 2016 (Part 1)

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]A.V.Khovanov
Innovative Gastro-absorption method. A novel cleansing system in prevention and treatment.
[/su_expand]

Icon
ENTEROSGEL COLUMBIA LECTURE, 2016 (Part 2)

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]A.V.Khovanov
Innovative Gastro-absorption method. A novel cleansing system in prevention and treatment.
[/su_expand]

Icon
APPLICATION OF ENTEROSGEL ENTEROSORBENT FOR TREATMENT OF INTOXICATION AND DIARRHEA SYNDROMES IN PATIENTS WITH AIDS DURING ANTIRETROVIRAL THERAPY, 2015

Yurchenko A.V., Nikolaev V.G., Mamyedova E.S., Antonenko Z.V., Fedorenko S.V., Riabokon S.V., Harytonyuk A.V., Babeshko Y.S.

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]1. Application of Enterosgel enterosorbent in the patients with AIDS in the development of adverse reactions to antiretroviral therapy promotes more rapid reduction of diarrhea and intoxication syndrome (disappereance of subjective complaints, reduction of mean values of intoxication indexes, rod nuclear cells and eosinophils, positive dynamics of reduce of transaminase average level).
2. No adverse reactions caused by Enterosgel has been identified during its application as a part of complex therapy of pathological conditions in HIV-infected patients.[/su_expand]

Icon
APPLICATION OF ENTEROSORBENTS IN THE TREATMENT OF INTESTINAL INFECTIONS IN CHILDREN WITH CONCOMITANT ATOPIC DERMATITIS, 2015

Usenko D. V., Y. A. Gorelov, A. V. Rudyk

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]Acute enteric infections (AEI) are among the widely prevalent infectious diseases worldwide. The highest incidence of intestinal infections occur in pediatric populations [1]. The main reason is biodiversity pathogens AEI: bacteria, viruses and protozoa from different taxonomic groups. Bacterial AEI can cause the genera Salmonella, Shigella, pathogenic strains of E. coli, spp. Clostridium, spp. Campylobacter spp., spp. Staphylococcus spp. Klebsiella, etc. Viral AEI pathogens are group A rotaviruses and noroviruses, astroviruses, F adenoviruses, sapoviruses. Discusses the role of group C rotaviruses, bocaviruses, Aichi virus, parechovirus, coronaviruses, etc. in the development of acute gastroenteritis.[/su_expand]

Icon
ROTAVIRUS INFECTION IN NEWBORNS CHILDREN: CLINICAL PERFORMANCE, TREATMENT AND PROPHYLAXY, 2004

TUNDA I. P.

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]Health Care Practice has proposed effective preventive measures based on the results of clinical and virological studies and determining RVI leading risk factors in infants.

In the practice of maternity and neonatology departments, specialized clinical virological and microbiological monitoring of RVI in newborns has been offered for early diagnosis and prevention of nosocomial RVI.

In complex care unit optimum schemes and methods of administration of recombinant interferon - Laferon in the dose of 50-100,000 IU / kg 2 times a day, in enemas, within 3-5 days has been offered; Enterosgel in the dose of 5 g / kg 3 times a day orally for 5 days. To correct microflora, multyprobiotic Symbiter was applied in RVI treatment in 0.5 dose twice a day, orally, for 10 days.[/su_expand]

Icon
ENTEROSORBENT ENTEROSGEL IN CLINICAL PRACTICE, 2016

T. Miksa

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]ln order to assess the characteristics of the medical device ENTEROSGEL, establish the method of its use and the safety for users, this report was drawn up in the form of a critical evaluation of the relevant
published clinical studies conducted with ENTEROSGEL and with other at least partially comparable
medical devices already placed on the European market.

-Translation from the Czech language-[/su_expand]

Icon
EUROPEAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION/EUROPEAN SOCIETY FOR PEDIATRIC INFECTIOUS DISEASES EVIDENCE-BASED GUIDELINES FOR THE MANAGEMENT OF ACUTE GASTROENTERITIS IN CHILDREN IN EUROPE: UPDATE 2014

Alfredo Guarino, Shai Ashkenazi, Dominique Gendrel, Andrea Lo Vecchio, Raanan Shamir, Hania Szajewska

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]Gastroenteritis severity is linked to etiology, and rotavirus is themost severe infectious agent and is frequently associated with dehydration. Dehydration reflects severity and should be monitored by established score systems. Investigations are generally not needed. Oral rehydration with hypoosmolar solution is the major treatment and should start as soon as possible. Breast-feeding should not be interrupted. Regular feeding should continue with no dietary changes including milk. Data suggest that in the hospital setting, in non–breast-fed infants and young children, lactose-free feeds can be considered in the management of gastroenteritis. Active therapy may reduce the duration and severity of diarrhea. Effective interventions include administration of specific probiotics such as Lactobacillus GG or Saccharomyces boulardii, diosmectite or racecadotril. Anti-infectious drugs should be given in exceptional cases. Ondansetron is effective against vomiting, but its routine use requires safety clearance given the warning about severe cardiac effects. Hospitalization should generally be reserved for children requiring enteral/parenteral rehydration; most cases may be managed in an outpatients setting. Enteral rehydration is superior to intravenous rehydration. Ultrarapid schemes of intravenous rehydration are not superior to standard schemes and may be associated with higher readmission rates.[/su_expand]

Icon
CLINICAL AND EPIDEMIOLOGICAL FEATURES AND THERAPY OF COLIBACILLOSIS IN CHILDREN IN THE MODERN STAGE, 2009

Bondareva A. V.

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]The purpose of this work is optimization of colibacillosis diagnosis and therapy in children based on a study of clinical and epidemiological features on the modern stage.[/su_expand]

Icon
SAFETY DATA SHEET

Bioline Products s.r.o.

Icon
ABOUT EXPERIMENTAL PRECLINICAL SAFETY STUDYING OF THE MEDICINAL FORM OF A PREPARATION «ENTEROSGEL®,PASTE FOR INTAKE (SWEET)» GIVEN «TNK SILMA LTD.» (MOSCOW), 2010

[su_expand height="30" link_style="dotted" link_align="left" more_icon="icon: chevron-down" less_icon="icon: chevron-up"]THE STUDY DRUG SAFETY OF "ENTEROSGEL®, PASTA FOR INTAKE (SWEET)" ALLOWS TO RECOMMEND ITS SUBMISSION TO THE TO THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION AS LOW-TOXICITY DRUG AS THE PROCEDURE FOR EXPANDING INDICATIONS AND CHANGES IN INSTRUCTION FOR USE. [/su_expand]


Please rate this information
  • 0/5
  • 0 ratings
0 ratingsX
Very bad! Bad Hmmm Oke Good!
0% 0% 0% 0% 0%